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IntroductionLaser treatment of the anterior chamber angle seems to have 
been first described in 1961 by Zweng and Flocks using a xenon-
arc light source in cats, dogs, and monkeys [1]. Laser treatment 
of the human trabecular mesh work by puncturing Schlemm’s 
canal was performed initially by Krasnov [2], but the lower 
intraocular pressure (IOP) he described was short-lived [2]. 
Argon laser trabeculotomy in humans and monkeys was reported 
by Worthen & Wickham [3].  Subsequently, Ticho & Zuberman 
noted that Argon laser treatment of the angle wassuccessful in 
lowering IOP despite lack of permanent trabecular openings [4].Contemporary use of Argon laser trabeculoplasty (ALT) is 
basedon a report demonstrating safety and efficacy in a group 
of open-angleglaucoma patients in 1979 by Wise & Witter [5]. 
In 1998, Latina and colleagues utilized a frequency-doubled 
neodymium:yttrium – aluminum – garnet (Nd:YAG) non-
thermal laser to lower IOP successfully in patients with open-
angle glaucoma [6]. This laser works by utilizing selective photothermolyis, selectively targeting melanin and melanin 
laden cells with minimal collateral damage to adjacent structures, 
and hence is referred to as selective laser trabeculoplasty (SLT) 
[7,8].Although other lasers have been utilized for laser 
trabeculoplasty, ALT and SLT appear to be the most common 
methods employed.Very few publications have compared these 
 
two laser modalities, and this review examines evidence for 
short and longer term efficacy and safety based on these studies 
[9-20].  One of these studies was pivotal in obtaining FDA 
approval for the SLT in the USA [21].
Methods 
A search for studies comparing SLT to ALT in open angle 
glaucoma were conducted using PubMed and Google.  Key search 
terms were selective laser trabeculoplasty and argon laser 
trabeculoplasty and the search was performed on February 14, 2017.
Efficacy
12 studies were found, and of these 2 involved a 
retrospective comparison, and 10 prospective. 3 of the studies 
were prospective randomized in design.  Other aspects of study characteristics including results are summarized in Table 1. Nearly all treatments involved applying laser to 180 degrees 
of the meshwork in eyesthat had received previous medical 
therapy.  The vast majority of studies had a preponderance of primary open angle glaucoma (POAG) patients compared to other subtypes of glaucoma.  All studies conclude that there 
were no significant differences in IOP lowering between SLT and 
ALT groups i.e. SLT is equivalent to ALT in short and longer term 
efficacy.
Table 1: Efficacy of SLT vs ALT:  summary of study design, findings, and limitations.`
Study Design/ Glaucoma type
Sample size 
(eyes)
Duration 
(longest)
Findings Limitations
Liu et al. [9]
Prospective randomized control trial; mostly POAG 42 (20 SLT and 22 ALT) 2 years
Significant IOP decrease of 11.1% 
after ALT (P=0.01) and 7.7% after 
SLT (P=0.01) with no statistical 
difference between the lasers (P>0.05)
Small sample size, both eyes 
treated although only first 
analyzed.  Low mean baseline IOP for both groups prior to laser
Si et al. [10]
Prospective randomized.  Only 
exfoliation patients enrolled. 76 (45 SLT, 31 ALT) 1 year
-6.2 mmHg and -8.6mmHg 
decrease with SLT and ALT, 
respectively. No significant difference.
Pretreatment IOP higher 
for ALT vs SLT (25.2 vs. 23.1 
mmHg; p=0.03).  36% loss to 
follow-up at 1 year.
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Bovell et al.  [11]
Prospective randomized control trial; mostly POAG 
with some XFG and PG
176 (89 SLT and 87 ALT) 5 years
Baseline similar in both groups.  
IOP lowering at 5yrs SLT –7.4 
± 7.3 mmHg vs ALT –6.7 ± 6.6 
mmHg; p=0.298.  Large but similar number of interventions in both groups over study period
Trial not designed for 5 year 
follow-up.  Moderate loss 
to follow-up (64 SLT eyes remaining and 56 ALT at 5yrs).
Almeida et al. 
[12]
Prospective, 
non-randomized interventional case series; mostly POAG 45 (25 SLT and 20 ALT) 6 months
IOP reduction with SLT 5.1 ± 2.5 
mmHg and ALT 4.4 ± 2.8 mmHg; 
p=0.38.
Small sample size, non-
randomized, short follow-up
Russo et al. [13]
Prospective randomized control trial; mostly POAG 120 (61 SLT, 59 ALT) 12 months IOP lowering with SLT 6.01 mmHg and ALT 6.12 mmHg p=0.794. No significant difference Small sample size
Best et al. [14]
Prospective non- randomized 165 (124 SLT and 41 ALT) 12 months Mean pressure reductions 1.8 mmHg (8.5 %) after SLT, and 2.1 mmHg (9.4 %) after ALT.  No 
significant difference
Damji et al. [15]
Prospective randomized control trial 176 (89 SLT and 87 ALT) 1 year Decrease in IOP at 1 year for SLT 5.86 mmHg and ALT 6.04 mmHg; p=0.846
IOP taken by one individual 
not masked to treatment.  
Some treated patients had prior ALT.
Van de veire S et 
al. [16]
Retrospective interventional case series; mostly POAG 56 (38 SLT and 18 ALT) 3-5 weeks IOP-reduction was 22.4% after ALT and 15.5% after SLT; p= 0.141
Small sample size, 
retrospective design with selection bias as patients preferentially received ALT 
or SLT depending on TM 
pigmentation. 4 eyes were 
excluded from analysis because of post treatment IOP rise.
Juzych et al. [17]
Retrospective chart 
review; only POAG patients enrolled 195 (41 SLT and 154 ALT)
Mean follow-
up 37.4±14.7 
months (SLT)  
and 33.6±17.0 months (ALT)
No statistically significant difference in IOP reduction 
between two groups using two different success criteria
Retrospective design with selection bias as patients 
underwent SLT or ALT based on availability
Martinez de la 
casa et al. [18]
Prospective non-randomized study; only POAG patients enrolled 40 (20 SLT and 20 ALT) 6 months
Reduction in IOP for SLT 22.2% 
(range 0–36.3%) and ALT 19.5% 
(range 0–30.2%).  P=0.741
Small sample size, unclear 
methodology of how patients 
assigned to SLT or ALT group
Popiela et al. [19]
Prospective randomized; mostly POAG
27 patients 
with one eye 
receiving SLT and the other ALT 3 months
Mean IOP drop -2.85 +/- 4.62 
mm Hg after SLT and -2.63 +/- 
3.60 mm Hg after ALT; p = 0.84). 
No significant difference in IOP 
reduction between two groups
Pretreatment IOP higher 
in ALT eyes vs. SLT (21.3 vs 
20.3; p=0.04).   No control for crossover effect.
Holló [20]
Prospective non- randomized study; mostly POAG
14 patients 
with one eye 
receiving SLT and the other ALT 1-18 months
IOP lowering varied between 
0-3mm Hg in each eye.  No 
significant difference in IOP 
lowering between eyes detected.
Small sample size
XFG: Exfoliation Glaucoma; XFS: Exfoliation Syndrome; PG: Pigmentary Glaucoma; POAG Primary Open Angle Glaucoma
Notes: For ALT all studies utilized a 50micron spot size and 0.1msec duration.  For SLT all studies utilized a 3nsec pulse and 400 micron 
spot.
It is worth noting that the effect of SLT and ALT diminishes 
with time at about the same rate.  This is illustrated in the study by 
Bovell et al. [11] which indicates that time to 50% failure in each 
group was approximately 2 years [11] (Figure 1). The definition 
of success employed in this study was 20% IOP lowering with no additional medical, laser, or surgical interventions.  The survival 
rate of persons after having received SLT was 44% at 3 years; 
at 4 years it was 38%; and at 5 years it was 25%. For patients 
who received ALT, survival at 3 yearswas 37%; at 4 years, 30%; 
and at 5 years, 27% It is worth noting that patients enrolled 
in the study were on maximal tolerated medical therapy, and 
required a large number of subsequent interventions (laser trabeculoplasty, incisional surgery, and cyclophoto coagulation) 
in both groups, over the 5-year follow-up period (49/89 SLT and 
33/87 ALT eyes).
How to cite this article: Fisseha A A. Safety and Efficacy of SLT vs ALT - Short and Longer Term Perspectives. JOJ Ophthal. 2018; 6(3) : 555687. DOI: 
10.19080/JOJO.2018.06.555687003
JOJ Ophthalmology 
Figure 1: Survival analysis of all patients in the study by Bovell et al. [11]. Success is defined as at least 20% lowering of intraocular 
pressure with no additional medical, laser, or surgical interventions (reproduced with permission from Elsevier).
SafetyThe most common complication reported in clinical studies 
of laser trabeculoplasty is an increase in IOP with highest spikes 
occurring within the first hour - although they may be delayed 
[22]. In a prospective randomized control trial, the reported 
incidence of increase in IOP greater than 6 mmHg from baseline 
1 hour after SLT and ALT in patients who were prophylactically 
treated for a pressure spike with an alpha adrenergic agonist 
was 3.4% in ALT-treated eyes and 4.5% in SLT-treated eyes [15]. 
These spikes typically resolve quickly with the addition of IOP 
lowering therapy [23]. If no prophylactic agent was used, the 
incidence of spikes in one SLT study was 25% [24], and in one 
ALT study 34% of eyes [25].
Heavy pigmentation of the trabecular meshwork has 
been strongly associated with IOP rises in both types of laser trabeculoplasties. There is a report of a case series by 
Harasymowycz et al. [22] with persistent elevation of IOP 
following SLT in eyes with heavily pigmented trabecular 
meshwork that required trabeculectomy [22]. The risk of such 
complications may be reduced by decreasing the power or 
treating less trabecular meshwork [15].Other complications of laser trabeculoplasty that appear 
to beseen much less with SLT than ALT include pain during 
treatment, blurry vision and conjunctival injection. The anterior 
chamber flare was significantly lower in the SLT group (13.3 SD 
6.3 photons/ms) than in the ALT group (20.7 SD 7.4 photons/
ms), P=0.003 in one study an hour after treatment [18].There have been reports of some cases that developed 
corneal edema from 24 hours up to one week after the surgery 
following SLT. It is not yet understood what may predispose a patient to corneal changes as a result of this procedure, although 
HSV stromal keratitis reactivation as a result of inflammatory 
cascade following laser treatment was attributed in one case. 
Routine use of topical anti-inflammatory drops may avoid this 
complication [26,27]. The Glaucoma Laser Trial reported a 46% 
rate of greater than or equal to 1 degree of peripheral anterior 
synechiae formation (PAS) after ALT.  PAS are extremely rare 
following SLT treatment [25].
There are also rare complications of SLT reported including 
transient and uneventful hyphemas [28,29] and a case of severe 
iritis with chorodal effusion [30]. Unlike ALT, SLT does not 
destroy the outflow apparatus of the eye that gives the latter theoretical advantages that may include improvedresponse to certain glaucoma medications that rely on improving trabecular 
outflow, potential for repeat treatment, and preservation of the 
Schlemm’s canal for possible future angle surgery.  
Future Directions for Clinical Research 
The use of lasers in glaucoma continues to evolve, with a 
trend towards primary and earlier intervention. Studies suggest 
a role for SLT as initial therapy for open-angle glaucoma and 
ocular hypertension and have demonstrated efficacy equal to 
medical therapy with prostaglandin analogue in one year [31-
33]. The advantages of initial laser therapy includes its safety as compared to long term use of medical therapy, compliance to treatment is not an issue and cuts costs related to medical therapy 
[34]. However, an important risk to mitigate is that patients may 
get lost to follow-up (some may feel their glaucoma is ‘cured’) 
and then return years later with uncontrolled glaucoma.  Hence, 
although more work needs to be done comparing SLT as primary therapy to other modalities of treatment,emphasis should also 
be given to  ensure patients and care partners are well educated 
about their disease and the importance of regular followup to 
monitor IOP, optic nerve and retinal nerve fiber layer structure, 
and visual field function.
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In the last decade and a half, SLT has proven to be equally 
effective as ALT in lowering IOP in primary open angle glaucoma 
and exfoliation glaucoma; however, future studies need to focus 
on 180 vs. 360 degree treatment, repeatability (when entire 360 degrees has been treated and additional treatment is being done) and its role, in comparison to ALT and other laser trabeculoplasty methods, in other glaucomas such as pigmentary glaucoma.   
References1. Zweng HC, Flocks M (1961) Experimental photocoagulation of the anterior chamber angle: a preliminary report. Am J Ophthalmol 52: 
163-165.2. Krasnov MM (1972) Laser puncture of the anterior chamber angle in 
glaucoma (a preliminary report). Vestn Oftalmol 3: 27-31.
3. Worthen DM, Wickham MG (1974) Argon laser trabeculotomy. Trans 
Am Acad Ophthalmol Otolaryngol 78(2): OP371-OP375.
4. Ticho U, Zauberman H (1974) Argon laser application to the angle 
structures in the glaucomas. Arch Ophthalmol 13: 455. 5. Wise JB, Witter SL (1979) Argon laser therapy for open angle glaucoma. 
Arch Ophthalmol 97(2): 319-322.6. Latina MA, Sibayan SA, Shin DH, Noecker RJ, Marcellino G (1998) 
Q-switched 532-nm Nd:YAG laser trabeculoplasty (selective laser 
trabeculoplasty). Ophthalmology 105(11): 2082-2090.7. Anderson RR, Parrish JA (1983) Selective photothermolysis: precise 
microsurgery by selective absorption of pulsed radiation. Science 
220(4596): 524-527 8. Kramer TR, Noecker RJ (2001) Comparison of the morphologic changes after selective laser trabeculoplasty and argon laser trabeculoplasty in 
human eye bank eyes. Ophthalmology 108(4): 773-779.9. Liu Y, Birt CM (2012) Argon Versus Selective Laser Trabeculoplasty in 
Younger Patients: 2-year Results. J Glaucoma 21(2): 112-115.10. Si FF, Kent S, Hutnik CM, Birt CM, Damji K, Harasymowycz P, Hodge WG, Pan YI, Crichton A. A Prospective Randomized Clinical Trial of 
Selective Laser Trabeculoplasty versus Argon Laser Trabeculoplasty 
in Open Angle Glaucoma and Ocular Hypertension Secondary to 
Pseudoexfoliation. Abstract presented at: Association for Research 
in Vision & Ophthalmology Annual Meeting; May 6-10, 2012; Fort 
Lauderdale, FL; ARVO E-abstract 6351.11. Bovell AM, Damji KF, Hodge WG, Rock WJ, Buhrmann RR, et al. (2011) 
Long term effects on the lowering of intraocular pressure: selective 
laser or argon laser trabeculoplasty? Can J Ophthalmol 46(5): 408-413.12. Almeida ED Jr, Pinto LM, Fernandes RA, Prata TS (2011) Pattern of 
intraocular pressure reduction following laser trabeculoplasty in 
open-angle glaucoma patients: comparison between selective and 
nonselective treatment. Clin Ophthalmol 5: 933-936.
13. Russo V, Barone A, Cosma A, Stella A, DelleNoci N (2009) Selective laser 
trabeculoplasty versus argon laser trabeculoplasty in patients with 
uncontrolled open-angle glaucoma. Eur J Ophthalmol 19(3): 429-434.
14. Best UP, Domack H, Schmidt V (2007) Pressure reduction after selective 
laser trabeculoplasty with two different laser systems and after argon 
laser trabeculoplasty--a controlled prospective clinical trial on 284 
eyes. Klin Monbl Augenheilkd 224(3):173-179.15. Damji KF, Bovell AM, Hodge WG, Rock W, Shah K, et al. (2006) Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from 
a 1-year randomised clinical trial. Br J Ophthalmol 90(12): 1490-1494.16. Van de Veire S, Zeyen T, Stalmans I (2006) Argon versus selective laser 
trabeculoplasty. Bull Soc Belge Ophtalmol (299): 5-10.
17. Juzych MS, Chopra V, Banitt MR, Hughes BA, Kim C, et al. (2004) 
Comparison of long-term outcomes of selective laser trabeculoplasty 
versus argon laser trabeculoplasty in open-angle glaucoma. 
Ophthalmology 111(10): 1853-1859.18. Martinez-de-la-Casa JM, Garcia-Feijoo J, Castillo A, Matilla M, Macias 
JM, et al. (2004) Selective vs argon laser trabeculoplasty: hypotensive 
efficacy, anterior chamber inflammation, and postoperative pain. Eye 
(Lond) 18(5): 498-502.19. Popiela G, Muzyka M, Szelepin L, Cwirko M, Nizankowska MH (2000) 
Use of YAG-Selecta laser and argon laser in the treatment of open angle 
glaucoma. Klin Oczna 102(2): 129-133. 20. Holló G (1996) Argon and low energy, pulsed Nd:YAG laser trabeculoplasty. A prospective, comparative clinical and morphological 
study .Acta Ophthalmol Scand 74(2): 126-131.21. Damji KF, Shah KC, Rock WJ, Bains HS, Hodge WG (1999) Selective laser trabeculoplasty v argon laser trabeculoplasty: a prospective 
randomised clinical trial. Br J Ophthalmol 83(6): 718-722.22. Harasymowycz PJ, Papamatheakis DG, Latina M, De Leon M, Lesk 
MR, et al. (2005) Selective Laser Trabeculoplasty complicated by IOP 
elevation in eyes with heavily pigmented trabecular meshworks. Am J 
Ophthalmol 139: 1110-1113. 
23. Barkana Y, Belkin M (2007) Selective Laser Trabeculoplasty. Surv 
Ophthalmol 52(6): 634-654.
24. Latina MA, Sibayan SA, Shin DH, Noecker RJ, Marcellino G (1998) 
Q-switched 532-nm Nd:YAG laser trabeculoplasty (selective laser trabeculoplasty): a multicenter, pilot, clinical study. Ophthalmology 
105(11): 2082-2088.25. (1995) Glaucoma Laser Trial Research Group: The Glaucoma Laser Trial: 1. Acute effects of argon laser trabeculoplasty on intraocular 
pressure. Arch Ophthalmol 107(8): 1135-1142.26. Moubayed SP, Hamid M, Choremis J, Li G (2009) An unusual finding of corneal edema complicating selective laser trabeculoplasty. Can J 
Ophthalmol 44(3): 337-338.27. Regina M, Bunya VY, Orlin SE, Ansari H (2011) Corneal edema and haze 
after selective laser trabeculoplasty. J Glaucoma 20(5): 327-329.28. Rhee DJ, Krad O, Pasquale LR (2009) Hyphema following selective 
laser trabeculoplasty. Oph Surg Lasers Imaging 40(5): 493-494.29. Shihadeh WA, Ritch R, Liebmann JM (2006) Hyphema occurring during 
selective laser trabeculoplasty. Ophthalmic Surg Lasers Imaging 37(5): 
432-433.
30. Kim DY, Singh A (2008) Severe iritis and choroidal effusion following 
selective laser trabeculoplasty. Ophthalmic Surg Lasers Imaging 39(5): 
409-411.
31. M Nagar, A Ogunyomade, D P S O’Brart, F Howes, J Marshall (2005) A randomised, prospective study comparing selective laser 
trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. Br J Ophthalmol 
89(11): 1413-1417.
32. McIlraith I, Strasfeld M, Colev G, Hutnik CM (2006) Selective laser 
trabeculoplasty as initial and adjunctive treatment for open-angle 
glaucoma. J Glaucoma 15(2): 124-130.
33. Katz LJ, Steinmann WC, Kabir A, Molineaux J, Wizov SS, et al. (2011) 
Selective Laser Trabeculoplasty Versus Medical Therapy as Initial Treatment of Glaucoma: A Prospective, Randomized Trial. J Glaucoma 
21(7): 460-468.
34. Cantor LB, Katz LJ, Cheng JW, Chen E, Tong KB, Peabody JW. Economic 
evaluation of medication, laser trabeculoplasty and filtering surgeries 
in treating patients with glaucoma in the US. Curr Med Res Opin 
24(10): 2905-2918. 
How to cite this article: Fisseha A A. Safety and Efficacy of SLT vs ALT - Short and Longer Term Perspectives. JOJ Ophthal. 2018; 6(3) : 555687. DOI: 
10.19080/JOJO.2018.06.555687005
JOJ Ophthalmology 
Your next submission with Juniper Publishers    
      will reach you the below assets• Quality Editorial service• Swift Peer Review• Reprints availability• E-prints Service• Manuscript Podcast for convenient understanding• Global attainment for your research• Manuscript accessibility in different formats          ( Pdf, E-pub, Full Text, Audio) • Unceasing customer service                           Track the below URL for one-step submission                    https://juniperpublishers.com/online-submission.php
This work is licensed under Creative
Commons Attribution 4.0 Licens
DOI: 10.19080/JOJO.2018.06.555687
